AlphaYou
Overview
Smart money at a glance
Filings to Sep 30, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 4 added, 5 cutMore cutting
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 29- Open
- $81.19
- 52-wk high
- $125.83
- High
- $81.99
- 52-wk low
- $80.84
- Low
- $80.97
- Prev close
- $81.42
- Mkt cap
- $9.85B
- P/E
- 16.9x
- Volume
- 2.70M
- Fwd P/E
- 14.9x
- Beta
- 0.54
- Div yield
- 5.93%
- P/S
- 1.5x
- P/B
- 117.1x
- Profit margin
- +8.7%
- Op margin
- +12.9%
- ROE
- +163.8%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about CLX filings
Are insiders buying or selling The Clorox Company (CLX) stock?
Neither. The Clorox Company (CLX) insiders filed no open-market purchases or sales in the 90 days to Sep 30, 2026, according to SEC Form 4 filings.
Which members of Congress have traded CLX recently?
None. No member of Congress disclosed a CLX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this CLX smart-money data?
This summary uses filings available on Sep 30, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net buying.
What funds are doing
Buys/Adds (1)
- MI
Millennium
$126.2M
added
Sells/Trims (2)
- P7
Point72
$165.0M
sold
- AQ
AQR
$78.8M
trimmed
What insiders are doing
Buys (1)
- BP
Breber Pierre R
$429K
bought
How top traders are positioned
No tracked top-trader positions in CLX right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 1.2% above what analysts expected.
Earnings per share
$1.64 expected
Reports Nov 2, 2026, in 33 days
Estimates as of Sep 29, 2026
EPS expected
$0.88 to $1.20
Revenue expected
11 analysts
Last 30 days
Analysts cutting estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.43B | $1.67B | $1.67B | $1.95B |
| Cost of what it sold | $833.0M | $951.0M | $948.0M | $1.14B |
| Gross profit | $596.0M | $722.0M | $722.0M | $804.0M |
| What it spent | ||||
| Research and development | $28.0M | $29.0M | $27.0M | $32.0M |
| Sales and admin | $277.0M | $262.0M | $229.0M | $514.0M |
| Other operating costs | $171.0M | $195.0M | $182.0M | -$764.0M |
| Total operating expenses | $476.0M | $486.0M | $438.0M | -$218.0M |
| What was left | ||||
| Operating profit | $120.0M | $236.0M | $284.0M | $1.02B |
| Interest on debt | $23.0M | $25.0M | $27.0M | $55.0M |
| Profit before tax | $107.0M | $215.0M | $256.0M | $213.0M |
| Tax | $25.0M | $54.0M | $65.0M | $46.0M |
| Net profit | $80.0M | $157.0M | $187.0M | $163.0M |
| EBITDA | $186.0M | $295.0M | $341.0M | $99.0M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace